APAC IPOs & Placements, Aequitas Research

Clarence Chu

At Aequitas we cover all IPOs and placements across Asia-Pac with a deal size of at least US$100m. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

APAC IPOs & Placements

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

Sahajanand Medical Technologies Ltd / Equity Capital Markets

Sahajanand Medical Technologies Ltd (544309Z IN)

<ul>
<li>
<a href="https://www.smartkarma.com/entities/sahajanand-medical-technologies-ltd" target="_blank" data-smartkarma-citation="entities:35324:1" rel="noopener">Sahajanand Medical Technologies Ltd (544309Z IN)</a> is looking to raise US$202m in its upcoming India IPO. The deal will be run by Axis Capital, Bank of America, Edelweiss and UBS.</li>
<li>Sahajanand Medical Technologies is a medical devices company that researches, designs, develops, manufactures and markets vascular devices.</li>
<li>The product portfolio is led by its flagship coronary stent, Supraflex Cruz, where the product had been implanted in over 400,000 patients globally as of Mar 2021.</li>
</ul>



Sahajanand Medical Technologies Ltd (544309Z IN) is looking to raise US$202m in its upcoming India IPO. The deal will be run by Axis Capital, Bank of America, Edelweiss and UBS.
Sahajanand Medical Technologies is a medical devices company that researches, designs, develops, manufactures and markets vascular devices.
The product portfolio is led by its flagship coronary stent, Supraflex Cruz, where the product had been implanted in over 400,000 patients globally as of Mar 2021.


FSN E-Commerce Ventures (Nykaa) (NYKAA IN)

CE Info Systems (MapmyIndia) (1052633Z IN)

RateGain Travel Technologies (RATEGAIN IN)

Sahajanand Medical Technologies Pre-IPO Tearsheet